Search
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnIt is secreted by the D cells of the islets to inhibit the release of insulin and glucagon, and is also generated in the hypothalamus, where it inhibits the release of growth hormone and thyroid-stimulating … Prosomastatin is further process into two active forms, somatostatin-14 (SST-14) and somatostatin-28 (SST-28), an extended SST-14 sequence to the N-terminus [A20384].
Duvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigational[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585] … Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma
Vepdegestrant
go.drugbank.com/drugs/DB19006ApprovedInvestigational[A275508, A275509] On May 1, 2026, the FDA granted approval for vepdegestrant tablets under the trade name VEPPANU. … [A275507, A275509] It serves as an advanced option to address the clinical challenge of endocrine-resistant breast cancer subtypes.
Xanthan gum
go.drugbank.com/drugs/DB11253ApprovedXanthan gum is a direct food additive permitted for direct addition to food for human consumption by the FDA. It is used as a thickening agent and stabilizer in emulsions. … Xanthan gum is a polysaccharide gum derived from* Xanthomonas campestris* by a pure-culture fermentation process and purified by recovery with isopropyl alcohol.
Peginterferon alfa-2a
go.drugbank.com/drugs/DB00008ApprovedInvestigationalPeginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. … Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Tiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawn[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763] … [A1923,A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification.
Colestipol
go.drugbank.com/drugs/DB00375Approvedbe good candidates for using the agent owing to its physical effects on the gut. … results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaPheniprazine
go.drugbank.com/drugs/DB09250ApprovedWithdrawnPheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeNefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnNefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. … Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeImidafenacin
go.drugbank.com/drugs/DB09262InvestigationalIt is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical. … It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder.